Ginger Eatman thought she was safe after getting her second COVID-19 vaccination in February. But she kept wearing her mask, using hand sanitizer and wiping down the carts at the grocery store anyway. A few weeks later, she noticed a scratchy throat.
"By Wednesday morning, St. Patrick's Day, I was sick. I had congestion — a lot of congestion — and some coughing," says Eatman, 73, of Dallas, Ga.
Her doctor thought her symptoms might be allergies. But Eatman started feeling sicker. And then she suddenly lost her sense of smell. ...
So Eatman got tested for the coronavirus. It came back positive. ...
Eatman isn't alone in this experience. It's a long-recognized phenomenon called "vaccine breakthrough."
Regeneron Pharmaceuticals said Monday that a single administration of its monoclonal antibody cocktail reduced the risk that volunteers exposed to Covid-19 would develop the disease by 81%.
The National Institutes of Health (NIH) announced Wednesday that it's launching a study to gauge the risk of allergic reactions to the Pfizer-BioNTech and Moderna vaccines among certain individuals.
Six months after being diagnosed with Covid-19, 1 in 3 patients also had experienced a psychiatric or neurological illness, mostly mood disorders but also strokes or dementia, a large new study shows.
A new vaccine for Covid-19 that is entering clinical trials in Brazil, Mexico, Thailand and Vietnam could change how the world fights the pandemic. The vaccine, called NVD-HXP-S, is the first in clinical trials to use a new molecular design that is widely expected to create more potent antibodies than the current generation of vaccines. And the new vaccine could be far easier to make.
